49
Participants
Start Date
October 31, 2009
Primary Completion Date
August 31, 2011
Study Completion Date
August 31, 2012
TOK-001
2 capsules (325 mg each), once per day
TOK-001
4 capsules (325 mg each), once per day
TOK-001
6 capsules (325 mg each), once per day
TOK-001
3 capsules (325 mg each), once per day
TOK-001
3 capsules (325 mg each), once per day with supplement
TOK-001
6 capsules (325 mg each), split dose (3 capsules with breakfast, 3 capsules with dinner)
TOK-001
8 capsules (325 mg each), once per day
TOK-001
8 capsules (325 mg each), split dose (4 capsules with breakfast, 4 capsules with dinner)
Roswell Park Cancer Institute, Buffalo
Johns Hopkins Hospital, Baltimore
Greenville Hospital System University Medical Center, Greenville
Comprehensive Cancer Centers of Nevada & US Oncology Research, Las Vegas
UCLA, Los Angeles
San Bernardino Urological Associates, San Bernardino
University of Washington/Seattle Cancer Care Alliance, Seattle
Dana Farber Cancer Institute, Boston
Lead Sponsor
LTN PHARMACEUTICALS, INC.
INDUSTRY